IP Library Granted Patent US 8,906,604
Granted Patent B2
US 8,906,604 · App. 13/915,195 · Granted Dec 9, 2014

Store-operated calcium cellular assay

Inventors: Gayatri Venkiteswaran (Bangalore, IN); Gaiti Hasan (Bangalore, IN)
Assignee: National Center for Biological Sciences
G01N33/5008A61K31/343A61K31/341A61K31/27G01N33/5038
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,906,604
App. No.
13/915,195
Granted
Dec 9, 2014
Kind
B2
Abstract

The present technology provides a cell based assay for identifying compounds that modulate store-operated ionic calcium levels using itpr mutant cell lines, such as itpr-ku cells, which have abnormal ionic calcium levels.

Claims (9)

1. A kit for identifying a compound that modulates store-operated calcium entry (SOCE) level in a cell, comprising:

at least one mutant mammalian and/or avian cell, wherein the mutant mammalian and/or avian cell comprises a residual SOCE level and expresses a single 1,4,5-inositol triphosphate receptor (InsP 3 R) gene (itpr) product wherein the itpr gene encoding the single InsP 3 R gene product consists of an itpr ka1091/ug3 mutant, and wherein the itpr ka1091/ug3 mutant contains G1891S and S224F point mutations; and at least one control cell.

2. The kit of claim 1 , wherein the control cell is selected from the group consisting of: (i) a wild-type, normal cell, and (ii) a cell having wild-type calcium ion release.

3. The kit of claim 1 , wherein the mutant mammalian cell or the mutant avian cell is selected from the group consisting of a 3T3 cell, a BHK21 cell, an MDCK cell, a HeLa cell, a PtK1 cell, an L6 cell, a PC12 cell, an SP2 cell, a COS cell a 293 cell, a CHO cell, a DT40 cell, an R1 cell, and E14.1 cell, an H1 cell, and an H9 cell.

4. The kit of claim 1 , further comprising a component for calcium imaging.

5. The kit of claim 4 , wherein the component for calcium imaging comprises a fluorescent dye.

6. The kit of claim 5 , wherein the fluorescent dye comprises fluo-4.

7. The kit of claim 1 , further comprising thapsigargin.

8. The kit of claim 1 , wherein the mutant mammalian cell is a murine cell.

Assignments (4)
RELEASE OF SECURITY INTEREST IN PATENTS, RECORDED ON JANUARY 29, 2019 AT REEL 048373 FRAME 0217 Recorded Sep 22, 2025
From: CRESTLINE DIRECT FINANCE, L.P., AS COLLATERAL AGENT
To: EMPIRE TECHNOLOGY DEVELOPMENT LLC
Reel/Frame 072936/0464 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2019
From: CRESTLINE DIRECT FINANCE, L.P.
To: EMPIRE TECHNOLOGY DEVELOPMENT LLC
Reel/Frame 049924/0794 →
SECURITY INTEREST Recorded Jan 29, 2019
From: EMPIRE TECHNOLOGY DEVELOPMENT LLC
To: CRESTLINE DIRECT FINANCE, L.P.
Reel/Frame 048373/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2013
From: VENKITESWARAN, GAYATRI; HASAN, GAITI
To: NATIONAL CENTER FOR BIOLOGICAL SCIENCES
Reel/Frame 030954/0626 →
Continuity (2)
Continuation 12628064 · Nov 30, 2009
Related Publication 20130260409A1 · Oct 3, 2013